WebNov 12, 2024 · Choriocarcinoma syndrome is a rare clinical entity with advanced, high volume choriocarcinomatous tumors and markedly elevated B-hCG (>50,000 IU/L). Recognition is important because the diagnosis of this syndrome identifies poor prognosis without mortality-proven management options. WebA total of 57% of patients had a high metastatic burden and 60% of patients received docetaxel. The median follow-up for the ADT + docetaxel (n = 355) and the ADT + docetaxel + abiraterone (n = 355) was 36 months. The median time to discontinuation of abiraterone in the abiraterone group was 31.4 months.
Effect of geometric distortion correction on thickness and volume ...
WebDec 22, 2024 · Patient is diagnosed with biochemical recurrence of prostate cancer with high-volume castration-sensitive metastatic disease Germline genetic testing is negative Treatment for Recurrence Patient wishes to receive oral treatment with good quality of life so he can continue to be involved in his grandchildren’s activities WebAbout 47% of American adults have high blood pressure, according to the U.S. Centers for Disease Control and Prevention. About half of men and 44% of women have high blood … imp219-1 firmware
ASCO 2024: First Results of PEACE-1: A Phase 3 Trial with a
WebApr 27, 2024 · We’re used to thinking about prostate cancer as high volume vs low volume. We didn’t see that in this trial. ... M1b, and M1c. Visceral disease represented about 17%, … WebJan 31, 2024 · Long-term follow-up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall … WebJul 1, 2024 · Disease volume was classified as high volume (≥4 bone metastases or visceral metastases) versus low volume. Results: Among 424 patients (88% white), 213 (50%) had high-volume disease and 211 (50%) had low-volume disease, 275 (65%) had de novo metastatic disease, and 149 (35%) had metastatic recurrence of nonmetastatic disease. imp221-1es firmware